IntelGenx Technologies Corp. (IGXT)

Market Cap	29.17M
Revenue (ttm)	1.05M
Net Income (ttm)	-11.03M
Shares Out	174.66M
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	37,230
Open	0.159
Previous Close	0.174
Day's Range	0.159 - 0.169
52-Week Range	0.090 - 0.224
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About IntelGenx Technologies

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pa...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 50
• Stock Exchange: OTCMKTS
• Ticker Symbol: IGXT

Financial Performance

In 2023, IntelGenx Technologies's revenue was $1.04 million, an increase of 9.37% compared to the previous year's $950,000. Losses were -$9.93 million, -7.14% less than in 2022.